Abstract: Intracellular aggregates of the alpha-synuclein protein result in cell loss and dysfunction in Parkinson's disease and atypical Parkinsonism, such as multiple system atrophy and dementia with Lewy bodies. Each of these neurodegenerative conditions, known collectively as alpha-synucleinopathies, may be characterized by a different suite of molecular triggers that initiate pathogenesis. The mechanisms whereby alpha-synuclein aggregates mediate cytotoxicity also remain to be fully elucidated. However, recent studies have implicated the cell-to-cell spread of alpha-synuclein as the major mode of disease propagation between brain regions during disease progression. Here, we review the current evidence for different modes of alpha-synuclein cellular release, movement and uptake, including exocytosis, exosomes, tunneling nanotubes, glymphatic flow and endocytosis. A more detailed understanding of the major modes by which alpha-synuclein pathology spreads throughout the brain may provide new targets for therapies that halt the progression of disease.
Alpha synuclein
Alpha synuclein (α-syn) is a 140 amino acid, soluble protein found predominantly within the central nervous system (CNS), and is enriched in the peripheral nervous system and circulating erythrocytes (Barbour et al., 2008; Theillet et al., 2016; Weinreb et al., 1996) . The normal role of α-syn remains unclear, however high concentrations of the protein exist within neuronal presynaptic terminals, indicating potential function(s) in synaptic transmission (Cheng, Vivacqua and Yu, 2011) . Multiple specific roles have been proposed for α-syn, including SNARE protein regulation, production of dopamine and regulation of synaptic vesicle recycling (Burre et 
Alpha-Synuclein in Disease
Intracellular inclusion bodies comprised primarily of misfolded and aggregated α-syn are the neuropathological hallmark of a group of neurodegenerative diseases with overlapping complex clinical phenotypes. These are known collectively as α-synucleinopathies and include Parkinson's disease (PD), multiple system atrophy (MSA) and dementia with Lewy bodies (DLB) (McCann et al., 2014) . PD patients develop characteristic motor dysfunction such as bradykinesia, tremor, rigidity and postural instability which are collectively known as Parkinsonism. As the disease progresses patients often develop depression, anxiety and dementia in advanced stages (Sveinbjornsdottir, 2016; Menza, Robertson-Hoffman and Bonapace, 1993) . DLB patients present with Parkinsonism and cognitive impairment such as hallucinations, fluctuations in alertness and short-term memory with a relatively rapid progression and decline (McKeith et al., 2004) . MSA is classified into two subcategories, based on α-syn distribution, pattern of spread, neurodegeneration and clinical phenotypes. MSA-P (Parkinson's) patients typically display a combination of parkinsonian-like symptoms, such as tremors and bradykinesia, whilst MSA-C (cerebellar ataxia) cases present with signs of ataxia and gait disturbance (Longo, Fanciulli and Wenning, 2015; Ubhi, Low and Masliah, 2011) . Both forms also display autonomic dysfunction in addition to other symptoms. α-Synucleinopathies exhibit overlap with regard to brain regions affected, with all three disorders displaying neuronal loss, particularly of dopaminergic neurons, within the substantia nigra in the midbrain as well as the basal ganglia (Braak et al., 2003; Ubhi, Low and Masliah, 2011) . Differences in disease duration also exist between the three diseases, with MSA patients surviving for around 8 years after symptoms appear, whilst PD and DLB typically survive more than 10 years (Marttila and Rhine, 1991; Wenning and Stefanova, 2009; Williams et al., 2006) In addition to neuronal loss, α-synucleinopathies each display characteristic inclusions, with the predominant types in PD and DLB known as the Lewy body (LB) and the Lewy neurite (LN). LBs and LNs both share similarities, such as their composition of filamentous fibrillar α-syn, ubiquitin and neurofilament and are found in surviving neurons upon autopsy (Spillantini et al., 1997; Engelender, 2008 , Braak et al., 1999 Galloway, Mulvihill and Perry, 1992) . However, these inclusions have distinctly different morphologies, with LBs being largely spherical whilst LNs have rod-or snake-like morphologies (Braak et al., 1999) . Work by Kanazawa et al., using 3D reconstruction of confocal images revealed that both LB and LN share the same structural components of an inner filamentous α-syn and ubiquitin layer coated by neurofilament (Kanazawa et al., 2008) , also finding LB/LN intermediary like structures sharing the same characteristics. This suggests LNs may be an earlier LB stage, thus explaining the abundance of these inclusions together in affected brain regions. MSA inclusion bodies, termed glial cytoplasmic inclusions (GCIs), share similarities to LBs and LNs, containing filamentous α-syn and ubiquitin, however, also contain αB-crystallin and tau (Miki et al., 2010; Tu et al., 1998) . GCIs have a triangular or sickle-like morphology (Miki et al., 2010; Grazia Spillantini et al., 1998) and occur predominantly in oligodendrocytes (Ahmed et al., 2012) . Although oligodendrocyte lineages are known to express α-syn mRNA at low levels both normally and in MSA, α-syn is expressed primarily in neurons, implicating uptake as the main source of α-syn in GCIs (Asi et al., 2014; Djelloul et al., 2015) .
Although the majority of cases of α-synucleinopathy are sporadic, rare missense mutations in the α-syn gene (SNCA) have been found to cause familial PD phenotypes and α-syn pathology with some variants also displaying pathology similar to MSA (Lesage et al., 2013; Polymeropoulos, 1997) . Gene duplications and triplications have also been reported resulting in increased α-syn synthesis and PD phenotypes (Chartier-Harlin et al., 2004). Furthermore, genome wide association studies have highlighted SNCA as one of the strongest risk loci for developing PD, strengthening the link to α-syn as a causative agent in α-synucleinopathies Reynolds et al., 2007) . Phosphorylation at Serine 129 can be associated with an insoluble, oligomeric β-sheet conformation and has been shown to be the dominant modification in MSA and DLB (Cookson, 2009; Anderson et al., 2006) ). Oligomeric α-syn is then thought to aggregate into fibrils, the characteristic form of α-syn observed in diseases such as PD. These fibrils together with a multitude of other proteins form the pathological inclusion bodies. The central hydrophobic region of α-syn termed non-Aβ Component (NAC), comprising residues 61-95, is the region susceptible to β-sheet formation (Ueda et al., 1993 ). It has been described recently that α-syn can form strains in vitro other than fibrils which display different binding, penetration and toxic characteristics as well as a different structure, such as α-syn ribbons . Whilst ribbons have not yet been detected in humans, various strains of oligomers have been observed (Gai et al., 2003; Pountney et al, 2004) . These different strain types may account for some of the differences observed in different α-synucleinopathies, such as inclusion body morphology or cell types affected.
Alpha-synuclein and disease spread
The current model of tissue spread of α-syn pathology, devised by Braak et al., in 2003 proposed that LB in sporadic PD originate within the olfactory bulb and medulla oblongata and later spread to the substantia nigra, midbrain and basal ganglia (Braak et al., 2003) . In MSA-P, degeneration occurs within the nigrostriatal region due to appearance of α-syn in the substantia nigra and putamen, later spreading to the frontal cortex (Paviour et al., 2007) . MSA-C has recently been proposed to have a 4-phase stage pathology, whereby it begins in the cerebellar subcortical white matter and olivo-cerebellar fibres within the medulla, later spreading to the basal ganglia, neocortex, amygdala and hippocampus (Brettschneider et al., 2016) . A spatial relationship between GCIs and myelinated axons was also observed, revealing that GCIs occur largely in myelinating oligodendrocytes. Consensus guidelines of the DLB Consortium aim to classify DLB pathology via LB presence and density in specific brain regions in conjunction with the presence of Alzheimer's-like degeneration. Several recent studies have proposed pathological α-syn to behave in a prion-like manner. Prions are classified based on their transmissibility as well as their ability to interact with and convert healthy proteins (PrP C ) into the pathological form (PrP SC ) (Kovacs and Budka, 2008; Goedert, 2015) . Pathological α-syn displays many of these characteristics. The NAC region of α-syn contributes to stabilizing the β-sheet conformational change (Iwai, 2000; Theillet et al., 2016; Rodriguez et al., 2015) . α-Syn fibrils have been shown to be insoluble, and persist in the extracellular environment, thus aiding transmissibility (Cookson, 2009 ). Additionally, recent work has shown that certain α-syn species can operate in a prion-like manner to auto-catalyze misfolding and aggregation, thereby resulting in neurotoxicity and neurodegeneration (Goedert, 2015). reported glial inclusion body formation in mice injected with dispersed GCI material. Recasens et al. (2014) showed that human LB enriched fractions were able to induce PD-like pathology in macaque monkeys (Recasens et being termed a prion-like disease (Prusiner et al., 2015) . This discovery led to speculation that α-syn in MSA is of a different strain than that of PD or DLB due to the presentation of prion characteristics with the inoculation of MSA homogenates and the absence of these with PD and DLB homogenates. This may also explain the presence of inclusion bodies in and degeneration of oligodendrocytes observed in MSA. Curiously, aggregated α-syn was observed primarily in neurons rather than reproducing the mostly glial inclusions observed in MSA tissue (Cykowski et al., 2015) . Interestingly, homogenates from PD and DLB patients failed to induce significant neurodegeneration or α-syn pathology in the same study. This raises the question of the identity of the pathogenic α-syn biochemical species in the different α-synucleinopathies and whether other proteins, in conjunction with α-syn are required for it to become prion-like.
Evidence for α-syn spread has also been observed in humans who received tissue grafts. Li et al. .These results give further credence to the proposition that pathological α-syn can transmit to healthy cells and promote further α-syn aggregation similar to prion proteins. These studies highlight the potential for extracellular α-syn to be taken up by CNS cells and cause neurodegeneration in a prion-like manner. Although routes of α-syn spread and uptake are still poorly understood, recent studies have begun to clarify how this may occur. The current review will discuss potential routes of pathological α-syn spread, including exosomal transport, tunneling nanotubes, microglia and the glymphatic system.
Extracellular α-syn, secretion and uptake
Several studies have demonstrated the existence of α-syn in the extracellular environment. showing that Hsp70 in conjunction with its co-chaperone DnaJ also regulates the release of α-syn from synapse (Fontaine et al., 2016) . This suggests that systems exist within the CNS to control and combat formation and spread of pathological α-syn oligomers, and that these regulatory systems are overloaded or non-functional in α-synucleinopathies. Peelaerts et al. (2015) explored the efficiency of extracellular spread of different α-syn strains comprising of oligomers, fibrils and ribbons in vivo, revealing that oligomers spread most efficiently (Peelaerts et al., 2015) . In addition, dopaminergic neurons were observed to take up and enact trans-synaptic transport of all α-syn types. Whilst free extracellular α-syn movement may explain neuron-neuron spread to neighboring neurons it cannot explain the occurrence of GCIs in MSA as oligodendrocytes are not connected to neuronal synapses or cases where α-syn pathology occurs in disconnected brain regions.
Neurons have another secretory mechanism at their disposal allowing for the release of cargo in the form of exosomes. Exosomes are 50-100nm vesicles that facilitate intercellular communication by transporting specific proteins (e.g. Heat shock proteins) or RNA (e.g. mRNA & miRNA) (Valadi et al., 2007; Gibbings et al., 2009; Lancaster and Febbraio, 2005) . Composed of raft lipids such as cholesterol, exosome formation can occur in one of two ways. They can be directly shed from the plasma membrane, in which the cellular membrane forms a small vesicular bubble on its extracellular surface with the cargo of interest inside before budding off the main cell (Beaudoin and Grondin, 1991) . Alternatively, exosomes can be formed inside the multi-vesicular body, which then fuses with the cell membrane in an exocytic fashion thereby releasing cargo vesicles into the extracellular environment (Denzer et al., 2000) . An example of this is oligodendrocytes releasing As discussed previously, the normal function of α-syn is thought to be related to vesicle recycling within the presynaptic terminal involving direct interaction with lipids, whereas, neuronal exosomes are produced via MVB-plasma membrane fusion or shedding of the neuronal membrane at the synapse (Von Bartheld This also has the effect of activating microglia from the surveying ramified state to the phagocytic amoeboid phenotype (black arrow). Activation is also caused when ramified microglia detect α-synuclein either in exosomes or free floating in extra cellular matrix. Astrocytic activation can lead to dysregulation of glymphatic circulation via loss of aquaporin-4 polarization to endfeet, causing turbulent flow. Oligodendrocytes can take up α-synuclein containing exosomes from neurons via endocytosis. Oligodendrocytes transfer α-syn to other oligodendrocytes either via exocytosis or TNTs, eventually releasing α-synuclein/GCIs through apoptosis/necrosis for phagocytosis by microglia. Oligodendrocytes may also release α-syn in exosomes. Microglia can engulf exosomes via macropinocytosis. Microglia perform phagocytosis on free floating and exosome-associated α-synuclein. Microglia may then propagate spread either via exosomes or α-syn via cell death or membrane leakage. II. F-actin TNTs exchange material between cells. In this illustration, an aggregate-bearing neuron (right) is transferring α-synuclein/LBs to an adjacent neuron (left) via a thick TNT causing spread of the pathological protein/inclusion body. III. Transportation of α-synuclein via exo-and endocytosis. A neuron (blue), is undergoing exocytosis and the exosomes are travelling toward the oligodendrocyte (purple). Once close to the cell membrane of the oligodendrocyte, the exosomes may undergo different modes of endocytosis. One mode (top) involves fusing with the membrane of a target cell leading to transfer of cargo. An alternate mode involves dynamin and clathrin mediated endocytosis, whereby the exosome binds to the receptor (black) which triggers its entry. Clathrin (green triangles) surrounds the budding vesicle whilst dynamin (grey circles) pinches the membrane from the vesicle. This clathrin coated vesicle will then be fused with lysosomes for degradation. Microglia are shown activating clathrin-dynamin mediated endocytosis as well as microglial activation by CD36 scavenger receptor and TLRs. Neurons have LAG3 and TM9SF2 receptors on the surface which when bound by fibrillar α-syn, mediate clathrin dependent endocytosis.
Macropinocytosis is an actin-dependent mechanism whereby membrane ruffling allows entry of material into a variety of cell types in vitro and can be utilized by immune cells, such as microglia, to initiate lysosomal degradation. Heparan sulfate proteoglycans on the surface of cells have been shown to mediate the entry of α-syn fibrils via macropinocytosis (Holmes et al., 2013) . Overall, current studies indicate that multiple mechanisms of exogenous α-syn cell entry exist. Further research is required to determine if other potential endocytic sites or receptors exist to facilitate α-syn entry into cells and whether therapeutic interventions can be developed to selectively inhibit uptake by healthy target cells. 
Tunneling Nanotubes

Microglia
Microglia, the principal immune-phagocytic cells of the CNS, display some characteristics required by a potential mechanism of α-syn intercellular spread (Kettenmann et al., 2011) . Under normal conditions, microglia exist in a resting state whereby they survey different brain regions for harmful or pathological molecules/proteins, detection of which causes a change from a resting to a phagocytic state (Jonas et al., 2012 ). This change is accompanied by a morphological change from ramified to amoebic, allowing microglia to perform phagocytosis for the breakdown of harmful agents (Jonas et al., 2012; Perry, Cunningham and Holmes, 2007) . This activation is typically reinforced with release of pro-inflammatory factors, such as interleukin-β and tumor necrosis factor-α for the recruitment of additional microglia to the site to allow for effective clearance (Neumann, Kotter and Franklin, 2008) .
Gliosis, the term used to describe activation of glial cells such as microglia and astrocytes, is a major pathological feature of MSA and to a lesser extent DLB and PD. Elevated microglial activation in areas corresponding to α-syn deposition and neurodegeneration has been observed in patients with PD, DLB and MSA via Positron Emission Tomography studies using a ligand to target activated macrophages and has been replicated in neuropathological studies of α-synucleinopathies (Fellner and Stefanova, 2012; Politis, 2012) . Whether this is just a correlate of neurodegeneration or actively contributes to disease pathogenesis is currently unknown, although there is some evidence to show that microglia may have an active role in α-synucleinopathies. Increased pro-inflammatory cytokines are observed in MSA cases (Kaufman et al., 2013; Wenning and Stefanova, 2009; Koga et al., 2015) . Activation of microglia is observed in PD, however the inflammatory response is not as widespread as in MSA (Nagatsu and Sawada, 2005; Tufekci et al., 2012). Gliosis is also observed in DLB, and whilst gliosis also occurs in Alzheimer's disease, it can be distinguished based on areas affected (Higuchi et al., 2000) . This difference in inflammatory profile may be related to different strains of α-syn as discussed earlier. Peelaerts et al., 2015 partially support this hypothesis, observing microglial activation to be most pronounced when exposed to fibrillar α-syn diffusing via the blood-brain barrier (Peelaerts et al., 2015) .
Microglia have been observed in vitro to take up exosomes released by oligodendrocytes containing α-syn via macropinocytosis, but lack the ability to effectively degrade fibrillar α-syn (Fitzner et al., 2011) . This inability to clear α-syn may be associated with impairment of the lysosomal pathway, the dominant mechanism associated with degradation after phagocytosis of α-syn and other pathological molecules. Previous studies have shown that lysosomal impairment is observed in PD, in both sporadic and familial cases, although this work has focused on neurons . It is conceivable that α-syn could attract and activate microglia which fail to completely clear α-syn and potentially cause neurodegeneration themselves through an excessive pro-inflammatory response (Tang and Le, 2015) .
Microglia have been shown to play an active role in the progression of multiple neurodegenerative diseases. Specifically, depleting microglia and blocking the synthesis of exosomes in mice has been shown to decrease tau deposition in nearby healthy cells (Asai et al., 2015) . This suggests a potential synergy between microglia and exosomes in pathological spread in neurodegenerative conditions and is potentially an important mechanism of spread in α-synucleinopathies. In mice injected with pathological α-syn aggregates, microglial activation was observed to have spread further away from the site of injection over three weeks than the diffusion of α-syn aggregates . Whilst there is little literature regarding microglia and their use of TNTs, TNTs or other systems may be employed for intercellular communication.
Macrophages have been shown to utilize both forms of TNT for material exchange and phagocytic clearance of bacterial species between themselves and other connected cells (Onfelt et al., 2004; Onfelt et al., 2006) . Given the functional relationship between microglia and macrophages, it is possible that α-syn aggregates could use TNTs for intercellular spread to microglia. One important characteristic of microglial cells is their plasticity, allowing them to travel to distal brain regions. That plasticity, in combination with the inability of microglia to degrade pathological α-syn effectively, could make microglia an effective transport hub for α-syn during disease.
Glymphatic Clearance
There is evidence to suggest that the glymphatic system, facilitated by astrocytes, may also be involved as a mechanism of spread in α-synucleinopathies. The glymphatic system is analogous to the lymphatic system and operates to circulate nutrients and remove waste products via exchange of interstitial fluid with cerebrospinal fluid (CSF). CSF flows into the perivascular space before being exchanged with interstitial fluid in the brain parenchyma. This process is facilitated by bulk flow due to pressure differentials and aquaporin-4 transporters on the endfeet of astrocytes which enclose the perivascular space (Jessen et al., 2015) . While α-syn clearance by the glymphatic system has yet to be determined, other aggregation-prone proteins, such as amyloid beta and tau, are cleared by the glymphatic system in models of Alzheimer's disease and Traumatic brain injury (Iliff et al., 2014; Iliff et al., 2012) . Additionally, phosphorylated α-syn has been found in the endfeet of astrocytes in a subset of MSA patients upon autopsy. While a recent study showed negative correlation between α-syn deposition and astrocytic aquaporin-4 expression in the temporal neocortex of PD patients (Hoshi et al., 2016) . This correlates with studies demonstrating that extracellular α-syn induces reactive astrogliosis . Lower levels of α-syn in the CSF of patients with α-synucleinopathies compared to neurologically normal and Alzheimer's patients has been observed which may indicate an impairment in α-syn clearance via the glymphatic system (Gao et al., 2015) . Investigating the clearance of α-syn via the glymphatic system in various in vivo models of α-synucleinopathies, combined with new functional glymphatic neuroimaging techniques in patients will help to assess any contributions of the glymphatic system to the pathophysiology occurring in alpha-synucleinopathies (Lundgaard et al., 2016 ).
Summary and Concluding Remarks
Currently, exosome transport is the most widely investigated mode of α-syn spread. There are however still many factors relating to exosomal spread that are unknown, such as whether α-syn transport via exosomes is limited to neuron-neuron or if it is also utilized by other cell types. The multitude of routes of exosome-mediated cellular uptake renders therapeutic intervention a challenging target, whereby a candidate molecule would need to prevent entry via diverse mechanisms. Gaps in knowledge also exist regarding TNTs. Evidence of transportation has been shown to exist in vitro, however its role in α-synucleinopathies in vivo is still unclear. The role of the immune response of both astrocytes and microglia is also contentious whether this is primarily protective or degenerative. There is evidence of microglia propagating and enhancing the spread of tissue pathology in diseases such as Alzheimer's disease, however further work on microglia is required concerning α-synucleinopathies Although multiple potential modes exist of α-syn spread in the brain, the pattern of spread in α-synucleinopathies is consistent between individual cases. Currently, α-syn spread according to the Braak staging scheme is predicted to occur between anatomically connected regions, forming a pattern based on α-syn spreading largely to neighboring regions. Yet vehicles such as exosomes and microglia have capabilities as long distance transporters to allow for spread to distal regions. In vivo, each of the mechanisms would be expected to occur either in stages or in concert. For example, gliosis involving increased activation of microglia and astrocytes may impair processes such as the glymphatic system. Thus, interactions between different modes of α-syn spread will further complicate successful therapeutic intervention, as multiple pathways may need to be targeted. Overall, future studies will need to investigate approaches to inhibiting the various potentially important mechanisms of α-syn spread in disease models which may identify novel targets for α-synucleinopathy therapies. 
